{"id":"2f0b742e-c842-45ea-8277-751cb12a9815","arxiv_id":"1908.03332","paper_version":1,"verdict":"CONDITIONAL","confidence":"MODERATE","novelty_score":4.0,"correctness_risk":"medium","formal_verification":"none","parameter_count":0,"one_line_summary":"A review that urges stroke researchers to rank neuroprotective treatments by testing them against progressively harsher in vitro ischemia and to combine preconditioning with acute drugs.","lead":"This review proposes a way to pick which stroke neuroprotection therapies deserve further testing: expose neurons in dishes to increasingly severe stroke-like conditions and see which treatments still help. The authors argue that preconditioning approaches, especially an omega-3 fatty acid called ALA, should be prioritized and combined with acute drugs.","discovery_kind":"review","skeptic_critique":{"model":"deepseek-v4-flash","headline":"The proposed OGD-rank filter lacks external validation and explicitly fails the authors' own ALA example, so its generality as a prioritization tool is unproven.","rationale":"The reader's CONDITIONAL verdict is appropriate, but the strongest justification is sharper than 'OGD is a proxy for severity'. The load-bearing premise is predictive validity: not whether OGD in a dish resembles stroke, but whether a therapy's plateau on an OGD-duration axis predicts clinical usefulness. The paper asserts this ('in vivo generally correlates quite well with in vitro results' in Section 4.1), but the evidence is retrospective, within-family, and largely self-cited. The O'Collins 2006 database, cited to motivate prioritization, shows no relationship between preclinical evidence strength and clinical trial selection; this is not direct evidence against in vitro ranking, but it underscores the need for validation. The manuscript itself flags an internal counterexample: ALA, their paradigmatic pleiotropic and nutraceutical conditioner, may fail the supra-lethal OGD test yet be more effective in vivo; they propose a parallel in vivo pathway rather than integrating it into the ranking. That means the proposed filter is not scope-limited to neuronal-targeted agents in the abstract, where it promises to identify the 'best conditioner or acute neuroprotective therapy' generally. A blinded retrospective or prospective validation against known outcomes would settle whether false negatives are rare, making the framework useful, or systematic, making it misleading. Until then, CONDITIONAL is right, not because of a lack of novelty, but because the central tool's operating characteristics are unspecified.","tokens_in":19607,"tokens_out":4455,"duration_ms":52870,"concrete_test":"Take a blinded panel of roughly 15 interventions with known in vivo effect sizes and clinical trial outcomes (e.g., MK-801, memantine, magnesium, NA-1, minocycline, hypothermia, ALA, 3-NPA, a TRPM7 inhibitor, and vehicle), run each through the standardized OGD-duration continuum in rodent cortical neurons and human iPSC-derived neurons, and pre-register the predicted rank order. Compare it with meta-analytic in vivo infarct reductions (O'Collins 2006; Sena et al. 2010) and clinical outcomes. If the Spearman correlation is weak, or if ALA, an in vivo-effective NVU-targeting agent, fails the in vitro test while clearly succeeding in vivo, then the framework cannot serve as a general 'fail early' prioritization tool without a stated scope restriction or a second assay.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The central claim depends on the OGD-continuum assay being a valid early filter: candidates that fail supra-lethal OGD can be deprioritized, and the survivors are the 'best'. This requires the in vitro rank order to be monotonically related to in vivo and clinical efficacy. No such validation is provided. Section 4.1 offers only selected retrospective examples (MK-801 > memantine > Mg), which are all NMDA-type antagonists, i.e., within-family screening rather than a general ranking. Section 5.2 cites Tauskela et al. 2016, the authors' own study, for the rank order but gives no independent in vivo translation of that panel. More importantly, Section 5.4 states that pleiotropic conditioners such as ALA 'may fail the supra-lethal OGD test in vitro but may well yield higher efficacy in vivo'. This is the paper's own promoted candidate. A prioritization test that systematically produces false negatives for a major therapeutic class, one the authors argue should be pursued, cannot identify the 'best' therapy unless the claim is restricted to neuron-targeted acute agents. The paper acknowledges this only as a parallel process, which weakens the abstract's unqualified promise.","agreement_with_reader":"agree"},"referee_report":{"model":"deepseek-v4-flash","summary":"This review/perspective addresses the failure of acute neuroprotection in human stroke trials and argues that the field lacks a strategy for prioritizing among the many candidate neuroprotective therapies and conditioning paradigms. The authors propose an in vitro framework in which cultured neurons or brain slices are subjected to progressively longer oxygen-glucose deprivation (OGD), generating a continuum of insult severity. They argue that rank orders of neuroprotection determined in this way can identify the 'best' acute therapies and preconditioning stimuli, and can guide the rational design of combinations, based on evidence that each intervention reaches a plateau and fails at some OGD duration. They illustrate this with their own studies of preconditioning and MK-801, and with alpha-linolenic acid (ALA) as a pleiotropic conditioner that may act through the neurovascular unit. The paper concludes by recommending the adoption of this prioritization mindset before committing to in vivo studies.","tokens_in":19809,"tokens_out":4037,"duration_ms":41848,"significance":"If the central claim were validated, the framework would provide a cheap, early, falsifiable filter for ranking neuroprotective candidates and combinations, addressing a genuine and important gap in stroke translational research. The paper usefully synthesizes the clinical and preclinical failure literature, identifies the prioritization problem clearly, and proposes concrete, testable in vitro strategies (OGD continuum, multi-electrode arrays). It also makes a constructive distinction between neuron-targeted and neurovascular-unit-targeting therapies. However, the significance is currently limited by the lack of external validation of the core predictive claim, the acknowledged counterexample of pleiotropic agents, and the heavy reliance on the authors' own prior work for the key rank-order evidence.","major_comments":[{"comment":"The abstract's unqualified claim that an appropriately designed in vitro approach can identify the 'best' conditioner or acute neuroprotective therapy is contradicted by the paper's own acknowledgment in Section 5.4 that pleiotropic agents such as ALA 'may fail the supra-lethal OGD test in vitro but may well yield higher efficacy in vivo.' Since ALA is presented as a lead candidate and a paradigm shift, the proposed filter would systematically deprioritize an entire therapeutic class that the authors themselves advocate. The claim must be restricted to neuron-targeted, direct-acting agents, or the paper must specify how the in vitro framework will be extended to incorporate neurovascular readouts. As written, the framework cannot serve as a general prioritization tool.","section":"Abstract and §5.4"},{"comment":"The evidence that in vitro OGD rank orders predict in vivo and clinical outcome is limited to a single family of NMDA-type antagonists (MK-801 > memantine > Mg). This demonstrates ordering within a mechanistic class, not across mechanistically diverse candidates. The paper provides no example in which an OGD-continuum rank order was independently confirmed by prospective in vivo translation. Without such external validation, the central claim that the assay can identify the 'best' therapy or conditioner remains an assertion rather than an evidence-based conclusion.","section":"§4.1"},{"comment":"The core ranking result for preconditioning rests almost entirely on one study from the authors' laboratory (Tauskela et al., 2016). The independent evidence cited (Liu et al., 1992; Shamloo and Wieloch, 1999; Ueda and Nowak, 2005) supports the more general plateau concept, but not the specific rank ordering of different preconditioners. The two additional references cited for ranking (Meloni et al., 2002; Freiberger et al., 2006) are explicitly described by the authors as 'limited in scope.' The manuscript should either provide a more systematic review of independent evidence or clearly frame the ranking as a working hypothesis that requires multi-laboratory confirmation.","section":"§5.2"},{"comment":"The conclusion calls for a 'parallel process' for neurovascular-unit-targeting therapies, but this process is not integrated into the proposed prioritization framework. It is therefore unclear how an investigator would choose between a top-ranked neuron-targeted drug from the OGD assay and a pleiotropic agent like ALA that fails the assay. The manuscript would benefit from explicit decision criteria or a flowchart specifying when the OGD-continuum assay is applicable and which alternative assays are required for pleiotropic candidates.","section":"§6"}],"minor_comments":[{"comment":"References Wang et al. 2006a and Wang et al. 2006b appear to be identical in title, journal, and page numbers; this is likely a duplication error that should be corrected.","section":"References (Wang et al.)"},{"comment":"In the text, 'Nietzche' should be spelled 'Nietzsche' in both instances.","section":"§5.2"},{"comment":"The text reads 'the ongoing FRONTIER trail'; 'trail' should be 'trial'.","section":"§2.3"},{"comment":"In the reference list, 'V ornov JJ' contains an erroneous space and should read 'Vornov JJ'.","section":"References (Vornov)"},{"comment":"The trial name is spelled inconsistently as 'FASTMAG' in Section 2.3 and 'FAST-MAG' in Section 4.1; please standardize.","section":"§2.3 and §4.1"},{"comment":"The terms 'ACUTE weak' and 'ACUTE strong' appear in the figure caption but are not defined in the main text; adding a brief definition would improve clarity.","section":"Figure 1"}],"recommendation":"major_revision","confidential_remarks":"This is a perspective/review rather than a primary research article, so the bar for proof of the central claim is lower than for an original study. However, the abstract and conclusions make a stronger assertion than the evidence supports, and the acknowledged ALA exception is a genuine logical inconsistency. The paper could become acceptable after clarifying the scope of the framework, adding an explicit validation strategy, and balancing the reliance on the authors' own prior work. The duplicate reference entry also suggests a need for more careful proofreading."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"Quick take: this is a well-written review-perspective arguing that stroke neuroprotection needs an early, evidence-based filter, and proposing graded oxygen-glucose deprivation (OGD) in vitro as that filter. The proposal is plausible but not validated, and the paper's own ALA example undercuts the general claim. I'd still send it out for serious peer review.\n\nThe best part is the framing: instead of asking how neuroprotection works, ask how it fails. The 'OGD continuum' idea—make the insult progressively harsher, see which drugs or preconditioners protect at longer durations, then combine treatments that fail at different plateaus—is concrete and testable. The 'preconditioning buys time' concept, where a strong preconditioner delays the point at which an acute NMDA antagonist is needed, is genuinely interesting. The authors also deserve credit for being candid about limitations: Section 5.4 explicitly says pleiotropic agents like ALA 'may fail the supra-lethal OGD test in vitro but may well yield higher efficacy in vivo,' and Section 6 concedes that NVU-targeting therapies should run as a parallel process. That honesty is real.\n\nThe soft spots are in proportion. First, there is no external validation that the in vitro rank order predicts in vivo or clinical efficacy. The examples given—MK-801 > memantine > Mg—are all NMDA-type antagonists, so that's within-family screening, not a general ranking. The one panel that tested diverse preconditioners is the authors' own 2016 study, with no independent in vivo translation. Second, the ALA caveat is not a minor footnote; it is a world-class counterexample. If your filter systematically deprioritizes an entire class of pleiotropic neurovascular agents, including the one you yourself are promoting, then the abstract's unqualified promise of identifying 'the best' therapy is overstated. Third, calling nutraceutical preconditioning a 'paradigm shift' is marketing, not analysis. The self-citation pattern is heavy but not inappropriate for a review that builds largely on the authors' own experimental work.\n\nWho is this for? Anyone working on translational stroke neuroprotection, especially people designing preclinical screening pipelines or thinking about combination therapies. It is not primary research; it is a programmatic argument. But it is a serious one, and it makes a falsifiable prediction: the OGD rank order should track in vivo efficacy for neuron-targeted agents. That prediction deserves to be tested, and the paper deserves a referee who will ask for that test rather than a desk rejection.\n\nMy recommendation: accept for peer review, with revisions that narrow the claims to neuron-targeted acute therapies and preconditioners, and add a clear statement that pleiotropic NVU-targeting agents require a separate validation path.","headline":"A useful, honest perspective proposing graded OGD as an early filter for stroke neuroprotectants, but the core predictive claim is unvalidated and the paper's own ALA example admits a major exception.","tokens_in":20334,"tokens_out":2043,"would_cite":false,"duration_ms":25994,"reading_group":"maybe","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"The stroke neuroprotection field should rank candidates early by deliberately making cultured neurons fail, using progressively longer oxygen-glucose deprivation, and then design combinations from each therapy's failure point.","keywords":["stroke neuroprotection","preconditioning","oxygen-glucose deprivation","in vitro screening","translational prioritization","combination therapy","ischemic tolerance","alpha-linolenic acid"],"falsifier":"Take a blinded panel of preconditioners and acute drugs, rank them by their OGD plateau in cultured neurons, then test the same panel in a standardized animal model with graded ischemia severity; a near-zero or negative correlation between the in vitro and in vivo rank orders would refute the prioritization claim.","tokens_in":19388,"feed_emoji":"🧠","tokens_out":7944,"duration_ms":84450,"temperature":0.7,"pith_summary":"After more than a hundred failed clinical trials of acute stroke neuroprotection, the field lacks a principled way to choose which of the many candidate therapies deserves translation. This review argues that prioritization should happen as early as possible, in cultured neurons or brain slices, by deliberately making the ischemic insult harder until most treatments fail. A graded oxygen-glucose deprivation (OGD) continuum sorts acute drugs and preconditioning stimuli by the duration of ischemia their protection can outlast, exposes each therapy's plateau of efficacy, and reveals where adding a second agent rescues protection. The authors' point is that failure, not success, should be the primary experimental readout: understanding why and when each therapy stops working gives an evidence-based rationale for combining acute neuroprotection with preconditioning. A sympathetic reader would take this as a proposal to reverse the field's mindset from \"how protection works\" to \"how protection fails,\" so that scarce resources go to the strongest candidates.","feed_headline":"Stroke therapies ranked by how long neurons survive oxygen loss","feed_subtitle":"A graded oxygen-glucose deprivation test could filter weak drugs and preconditioners before costly animal trials.","key_machinery":"The central object is the supra-lethal oxygen-glucose deprivation (OGD) continuum: progressively longer durations of glucose and oxygen withdrawal in cultured neurons or brain slices, from lethal to supra-lethal insults. It functions as a severity ladder that converts neuroprotection from a binary outcome into a measurable rank order. Each therapy hits a plateau at a characteristic insult duration, combinations push the plateau further, and the point of failure marks the neurotoxic pathway that must be targeted next.","core_discovery":"The central claim is that an appropriately designed in vitro approach, neuron cultures or brain slices exposed to increasing durations of oxygen-glucose deprivation (OGD), can identify the best acute neuroprotective therapy and the best preconditioning stimulus, and show how to combine them. In this framework, each monotherapy or conditioner protects up to a characteristic OGD duration and then fails, and the duration at which protection collapses provides a rank order of efficacy. At supra-lethal durations all tested preconditioners fail, coinciding with unchecked glutamate release, and protection can be restored by timely addition of an NMDA receptor antagonist; extending the insult further requires a cocktail of anti-Ca$^{2+}$ agents. Preconditioning thus buys time during the insult, after which acute pharmacology is needed. The authors also contend that pleiotropic agents acting on the neurovascular unit rather than only on neurons, with $\\alpha$-linolenic acid as their example, may fail the neuron-only test and need adapted in vitro models.","pith_inferences":["If the OGD continuum were applied to human iPSC-derived neurons with multi-electrode-array readouts, the same ranking logic could test whether rodent-derived rank orders hold for human tissue, directly addressing a major translational gap the paper identifies.","A systematic record of failure modes, which pathway saturates at which insult duration, could become a shared map for designing rational polytherapy, much as drug-repurposing libraries are shared today.","The framework implies that negative in vitro results should be published as informative data, since the current bias toward positive neuroprotection would hide exactly the failure curves the approach depends on.","Extending the same graded-insult logic to postconditioning and remote conditioning would test whether the buy-time relationship holds across conditioning modalities and species."],"forward_implications":["A candidate that protects only against mild OGD can be deprioritized before resources are spent on animal models.","Preconditioning should be evaluated not as protection per se but as a delay in the onset of failure, quantifying how much time it buys before acute therapy is required.","Combination strategies can be designed rationally from the failure point of the lead therapy: when a single pathway is overwhelmed, add an agent against the next pathway.","The plateau of in vitro protection implies that current single-drug clinical regimens are likely underdosed relative to what the brain requires, supporting combination or higher-potency approaches.","Pleiotropic therapies aimed at the neurovascular unit need separate in vitro assays because they may fail the neuron-only OGD test yet still succeed in vivo."],"supporting_citations":[{"why":"Establishes the core problem: 1,026 experimental stroke treatments with no evidence that clinically tested drugs outperformed the rest, motivating the need for prioritization.","marker":"(O'Collins et al., 2006)"},{"why":"Supplies the key data for the proposed framework: a panel of preconditioners ranked by survival under supra-lethal oxygen-glucose deprivation, and rescue by an NMDA receptor antagonist.","marker":"(Tauskela et al., 2016)"},{"why":"Shows that a cocktail of glutamate antagonists plus extracellular acidity allows neurons to survive longer OGD than any single agent, grounding the plateau-and-combination logic.","marker":"(Kaku et al., 1993)"},{"why":"Demonstrates that combining sodium channel blockade with glutamate receptor antagonism extends OGD survival beyond either alone.","marker":"(Lynch, III et al., 1995)"},{"why":"Identifies TRPM7 as an additional death pathway engaged during anoxic neuronal death, supporting the need for multi-target combinations at supra-lethal insults.","marker":"(Aarts et al., 2003)"},{"why":"Shows that sublethal ischemic preconditioning only delays damage when the index insult is prolonged, the in vivo precedent for the buy-time plateau.","marker":"(Liu et al., 1992)"},{"why":"Provides the pseudo-preconditioning concept: tolerance reflects delayed ischemic depolarization, explaining why preconditioning has a finite ceiling.","marker":"(Ueda and Nowak, Jr., 2005)"},{"why":"A review of magnesium preclinical data that predicted the phase III failure, illustrating how preclinical rank information could have guided candidate selection.","marker":"(Meloni et al., 2006)"},{"why":"Shows that delayed NMDA antagonist administration loses neuroprotective efficacy in culture, grounding the timing-and-potency constraints used to explain clinical failures.","marker":"(Hartley and Choi, 1989)"}],"fun_headline_variants":["Preconditioning buys time, then acute drugs must finish","Neuron survival time ranks stroke therapies, preconditioners","Find stroke therapy winners by when neurons die","In vitro oxygen-deprivation test ranks stroke neuroprotectants"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The whole ranking scheme assumes that how long cultured neurons survive increasingly severe oxygen starvation predicts which therapies work in real strokes, even though the paper concedes that neuron-only cultures may miss therapies that protect blood vessels and support cells.","fun_headline_variants_meta":{"raw":{"variants":["Preconditioning buys time, then acute drugs must finish","Neuron survival time ranks stroke therapies, preconditioners","Find stroke therapy winners by when neurons die","In vitro oxygen-deprivation test ranks stroke neuroprotectants"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000222,"raw_usage":{"total_tokens":1522,"prompt_tokens":1085,"completion_tokens":437,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":701,"completion_tokens_details":{"reasoning_tokens":372}},"tokens_in":701,"tokens_out":437,"duration_ms":5163,"temperature":1.0,"reasoning_tokens":372,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-14T14:15:57.453204+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"Take a blinded panel of preconditioners and acute drugs, rank them by their OGD plateau in cultured neurons, then test the same panel in a standardized animal model with graded ischemia severity; a near-zero or negative correlation between the in vitro and in vivo rank orders would refute the prioritization claim.","supporting_citations":[{"cited_title":"Ischemia","cited_arxiv_id":null,"evidence_quote":"Establishes the core problem: 1,026 experimental stroke treatments with no evidence that clinically tested drugs outperformed the rest, motivating the need for prioritization."}],"review_version":1}